What Are the 5 Stages of Huntington’s Disease?

Huntington’s disease (HD) is traditionally divided into five stages based on a person’s ability to carry out everyday tasks, scored on a clinical tool called the Total Functional Capacity (TFC) scale. The stages range from Stage 1, where someone is still largely independent, to Stage 5, where round-the-clock care is needed. While this framework has been the standard for decades, the reality of living with HD is messier than a neat five-step ladder: psychiatric symptoms can surface years before motor problems, progression speed varies enormously from person to person, and a newer biological staging system is beginning to reshape how researchers think about the disease entirely.

How the Five Stages Are Defined

The five-stage model comes from the Shoulson-Fahn system, which scores a person’s functioning across five domains: work, finances, domestic chores, activities of daily living, and the level of care they require. Each domain gets a rating, and the scores are added up to produce a TFC number between 0 and 13. Stage 1 corresponds to a TFC of 11 to 13, Stage 2 to 7 through 10, Stage 3 to 3 through 6, Stage 4 to 1 or 2, and Stage 5 to 0. The staging captures functional decline rather than specific symptoms, which means two people in the same stage can look quite different clinically. One person in Stage 2 might struggle mostly with balance and coordination; another might have more pronounced trouble with thinking and planning. The TFC score is what ties them together.

Clinicians and researchers sometimes simplify the five stages into two broader buckets. One validated approach classifies TFC scores of 7 to 13 as “early HD” (Stages I and II) and scores of 0 to 6 as “late HD” (Stages III and IV/V).¹ That binary split is handy for research, but for families trying to understand what comes next, the five-stage breakdown offers more resolution.

Stage 1: Still Independent, but Slipping

In Stage 1, a person has received a clinical diagnosis but can still live independently, hold down a job, handle money, and manage their own household. The TFC score sits at 11 to 13, and specialized care is not yet needed. Studies of early-stage patients define them as having a TFC of 11 or higher, an independence rating of 100, and a disease duration of fewer than four years.²

That does not mean life feels normal. The earliest functional cracks tend to show up at work. In one study of people transitioning into manifest disease, about two-thirds reported some loss of ability to do their usual job. Roughly half had trouble managing finances independently, and about a third found they could no longer drive safely.³ These declines were predicted by a combination of motor symptoms, cognitive difficulties, and depression, not just involuntary movements. That pattern is worth emphasizing: people and their families sometimes assume HD is mainly about chorea (the jerky, involuntary movements), but the first meaningful hits to daily life are often cognitive and emotional rather than purely physical.

Stage 2: Work Becomes Harder, Independence Narrows

Stage 2 (TFC 7 to 10) is where the cracks widen. A person can typically still work, but only with accommodations, reduced hours, or a shift to less demanding tasks. Driving often becomes unsafe or stops altogether. Household chores that require coordination and planning become harder. Chorea is usually more visible at this point, and balance problems may start to cause falls. Cognitive slowing becomes more obvious too, particularly in tasks that require switching between rules or processing information quickly.

The boundary between Stage 1 and Stage 2 is not a cliff; it is a gradual slide. A person might technically score in Stage 2 for months before anyone notices the change, especially if they have already quietly adjusted their routines. Stage 2 is often where the tension between wanting to maintain independence and needing to accept help becomes most acute. Families may disagree about when to stop driving, when to step back from financial decisions, and when to modify the home. These conversations are easier when everyone understands that TFC staging is a clinical tool, not a rigid timetable.

Stage 3: The Shift to Dependence

At Stage 3 (TFC 3 to 6), working outside the home is no longer realistic. Managing finances and household tasks independently is beyond reach. Motor problems become more disabling: chorea may be severe, voluntary movements slow and clumsy, and swallowing starts to become effortful. This is also the stage where many people with HD need structured daily assistance, whether from family, home aides, or a care facility.

Medication use tends to increase at this point. A large cohort study found that treatment for autonomic dysfunction (problems with things like bowel and bladder control, blood pressure regulation, and sweating) jumped sharply from Stage 3 onward. Treatment for aggression and irritability also rose, while treatments for chorea and depression that were common in earlier stages began to taper.⁴ This shift in medication profiles reflects how the disease’s symptom mix evolves: the emphasis moves from managing involuntary movement and mood toward managing bodily functions and behavioral challenges.

Stages 4 and 5: Advanced Disease and Full-Time Care

Stages 4 (TFC 1 to 2) and 5 (TFC 0) represent advanced and end-stage disease. By Stage 4, a person needs substantial help with virtually all activities, including dressing, bathing, and eating. Speech may be very difficult to understand, and swallowing problems become a serious medical concern. By Stage 5, total care is required. The person is typically bedridden or chair-bound, unable to communicate effectively through speech, and entirely dependent on caregivers for feeding, hygiene, and repositioning.

Weight loss is a persistent challenge in advanced HD. Progressive calorie burning from involuntary movements, combined with swallowing difficulties, reduced mobility, food cramming (stuffing the mouth before the previous bite is swallowed), and apathy that diminishes appetite, all make nutritional care complicated. High-calorie diets are generally recommended to slow weight loss.⁵ Decisions about feeding tubes often arise and are among the hardest conversations in HD care.

The leading cause of death in HD is respiratory illness, particularly aspiration pneumonia, which occurs when food, liquid, or saliva enters the lungs because of impaired swallowing.⁶ A Norwegian study found respiratory diseases were the most common immediate cause of death in about 44% of cases.⁷ A European prospective study reported pneumonia as the single most frequent cause, followed by other infections and, strikingly, suicide.⁸ Skin ulcers, choking episodes, and nutritional deficiencies are also common in the final stages.⁹

What Controls How Fast Someone Moves Through the Stages

The single strongest predictor of how quickly someone progresses is the length of the CAG repeat expansion in the huntingtin gene. HD is caused by an abnormally long stretch of CAG repeats; the longer the stretch, the earlier symptoms tend to appear and the faster they tend to worsen.¹⁰ A study tracking long-term progression confirmed that both the age at which decline begins and the rate at which it accelerates are heavily CAG-dependent, with decline continuing to speed up through at least Stage 2 disease.¹¹

But CAG length is not destiny. Two people with identical repeat lengths can follow very different trajectories. Researchers are still working to identify the other factors that speed up or slow down progression. There is growing evidence that physical activity may help. A systematic review found good evidence that aerobic and strengthening exercise can improve exercise capacity and performance in early- to middle-stage HD.¹² A cross-sectional study using Fitbit data found that higher activity levels correlated with better cognitive performance and day-to-day functioning in people carrying the HD gene expansion, though it could not prove the activity was causing the benefit rather than simply reflecting better health.¹³

Psychiatric and Cognitive Symptoms Do Not Follow a Neat Stage Order

The five-stage model is built around functional capacity, not mood or cognition. In practice, psychiatric symptoms like depression, irritability, and apathy can appear years before any motor diagnosis and can flare or recede unpredictably across stages. Apathy and repetitive, obsessive-type behaviors, in particular, tend to track with cognitive decline and worsen as thinking skills deteriorate.¹⁴ Irritability, on the other hand, can be severe in earlier stages and sometimes eases as the disease advances and apathy takes over.

This mismatch between motor staging and psychiatric reality can be confusing for families. Someone in Stage 1 or 2 might seem physically fine but be struggling with explosive anger, deep depression, or compulsive behaviors that strain relationships. Because the TFC score captures only what a person can do, not how they feel or behave, the staging can understate how much the disease is already affecting quality of life.

A Newer Biological Staging System

The traditional five-stage system has a significant blind spot: it only starts counting once symptoms are obvious enough for a clinical diagnosis. But brain changes in HD begin decades earlier, and researchers increasingly want a framework that captures the full arc of the disease from the moment someone inherits the expanded gene.

The Huntington’s Disease Integrated Staging System (HD-ISS), published in The Lancet Neurology, was designed to fill that gap. It uses biological, clinical, and functional assessments and starts at Stage 0: anyone born with 40 or more CAG repeats in the huntingtin gene, before any detectable sign of disease. Stage 1 marks the point where measurable biological changes (like brain volume loss on imaging) become detectable. Stage 2 is where clinical signs appear. Stage 3 is where functional decline sets in.¹⁵ The system’s goal is to create a common language for clinical research, especially for trials of drugs that might intervene before symptoms emerge.¹⁶

One promising tool for tracking progression across HD-ISS stages is a blood protein called neurofilament light (NfL). NfL levels in blood are higher in people carrying the HD mutation than in controls, and they climb with each disease stage. In one study, baseline NfL levels correlated with subsequent decline in cognition, overall functioning, and brain volume over time.¹⁷ A five-year prospective study confirmed that the yearly rate of NfL increase grows larger in more advanced stages, making it a useful biological yardstick for tracking where someone stands.¹⁸ Blood-based biomarkers like NfL are especially appealing because they do not require a brain scan, making repeated measurement practical.

Caregiver Burden Across the Stages

The impact on family caregivers is enormous and does not simply mirror the patient’s TFC score. One study found that subjective burden was already high at the earliest stage of HD, and that it was associated with how long someone had been living with the disease and with the presence of aggressive behaviors.¹⁹ In advanced disease, caregiver burden splits into distinct patterns. A prospective study identified four clusters of patient-caregiver pairs: among patients with advanced HD, those with high irritability and obsessive behaviors placed the heaviest and growing burden on caregivers, while more apathetic patients were associated with lower and even declining burden.²⁰

In other words, the behavioral profile matters more for caregiver wellbeing than the raw stage number. A calm, apathetic person in Stage 4 who needs physical care may be less exhausting for a family member than an irritable, aggressive person in Stage 2 who needs constant emotional management. Longitudinal data do show, though, that caregiver burden broadly tracks with clinical and biological progression over time.²¹

Juvenile Huntington’s Disease

When HD appears in childhood or adolescence, which usually requires a very long CAG repeat inherited from the father, the five-stage framework does not apply in any straightforward way. Children with onset in the first decade often present with rigidity and dystonia rather than chorea, along with speech difficulties and declining school performance. Teens whose symptoms begin in the second decade may look more like adults with HD, but the trajectory is compressed: disease progression is faster and survival shorter, particularly when CAG repeat lengths are very high.²² Juvenile HD is rare, making up a small fraction of all cases, but it is devastating to families and often harder to diagnose because clinicians may not think of HD in a child.

Huntingtin-Lowering Therapies and the Question of Slowing Stage Progression

No treatment today can stop or reverse the march through the five stages. Every available medication treats symptoms: antipsychotics and tetrabenazine-class drugs for chorea, antidepressants for mood, antipsychotics for aggression, benzodiazepines for anxiety and sleep. The goal of symptomatic management is to maintain quality of life, not to alter the underlying disease course.

The most ambitious experimental approach targets the root problem: the toxic huntingtin protein itself. Strategies under investigation include antisense oligonucleotides that block the huntingtin messenger RNA before it can be translated into protein, RNA interference techniques, and gene-editing tools.²³ An early-phase trial of one antisense oligonucleotide showed it could reduce huntingtin protein levels in cerebrospinal fluid.²⁴ Later-stage trials of that particular drug were halted due to safety concerns, but the general principle of huntingtin lowering remains the leading disease-modification strategy.²⁵ If any of these approaches ultimately succeed, the five-stage timeline could look very different for future patients.

When the Symptoms Fit but the Gene Test Does Not

About 1% of people who look clinically like they have HD turn out not to carry the huntingtin expansion. These are called HD phenocopies, and they are caused by a range of other genetic conditions. The most common culprits include mutations in C9orf72 (the gene best known for causing some forms of frontotemporal dementia and ALS), the gene behind spinocerebellar ataxia type 17, and JPH3 (responsible for HDL2). Rarer causes include prion disease mutations, chorea-acanthocytosis, late-onset Friedreich’s ataxia, and a handful of others.²⁶ Even with extensive genetic workups, most phenocopy cases remain without a definitive diagnosis.²⁷ This matters practically because the prognosis, inheritance pattern, and available treatments differ depending on the underlying cause. If someone has chorea, cognitive decline, and behavioral changes but tests negative for the HD expansion, pursuing additional genetic testing is important rather than assuming the HD test was wrong.

Predictive Testing and Its Psychological Landscape

For people with an affected parent, knowing whether they carry the expanded gene means knowing whether they will eventually progress through these stages. Predictive genetic testing has been available since the early 1990s, and research on its psychological effects is now decades deep. A landmark study found that people who received a result showing increased risk did not, on average, become more distressed over the following year; their depression scores actually declined modestly. Meanwhile, people who declined testing or remained in limbo fared worse psychologically than those who got a definitive answer, even a bad one.²⁸ A systematic review confirmed that distress levels were not straightforwardly linked to the test result itself; both carriers and non-carriers experienced fluctuations in emotional wellbeing over time, and the process was not psychologically neutral for anyone involved.²⁹ For many at-risk individuals, the uncertainty of not knowing is harder to live with than a confirmed positive result paired with time to plan.